Amplify Dynamics

Develops innovative ultrafiltration solutions for purification using acoustofluidics and microfluidics.

Website: https://amplify-dynamics.com/

Cover Block

PUBLIC

Field Value
Name Amplify Dynamics
Tagline Develops ultrafiltration solutions for purification using acoustofluidics and microfluidics
Stage Pre-Seed
Business Model B2B
Industry Cleantech / Climatetech (with biotech application in lipid nanoparticle purification)
Technology Type Hardware
Geography North America
Founders Gustavo (co-founder and CEO)
Funding Label Non-equity assistance
Lead Backer The Ganesha Lab

Links

PUBLIC

Executive Summary

PUBLIC

Amplify Dynamics is a pre-seed deeptech company commercializing an ultrafiltration platform built on acoustofluidics and microfluidics, with an initial wedge in purifying lipid nanoparticles (LNPs) used in advanced therapies [Amplify Dynamics website] [The Ganesha Lab]. The core technology was invented by co-founder and CEO Gustavo during doctoral research at the University of Chicago, giving the company a primary-source IP origin rather than a licensed-in starting point [Amplify Dynamics website]. The company has received non-equity assistance from The Ganesha Lab, a biotech-focused soft-landing and acceleration vehicle for Latin American founders entering North America, in two tranches dated January 1, 2024 and February 17, 2025 [Crunchbase]. No equity round, customer revenue, or production volume has been publicly disclosed, which is consistent with a hardware company still moving from prototype to early pilot. The strategic interest for investors is the intersection of two demand curves: the acceleration of mRNA and gene-therapy pipelines that depend on LNP delivery, and the pressure on contract development and manufacturing organizations (CDMOs) to raise yield and purity at lower cost. Over the next 12 to 18 months, the markers worth tracking are the first paid pilot with a CDMO or therapeutics developer, a priced equity round, and any peer-reviewed or regulator-facing data on purity and recovery rates versus tangential-flow filtration. This report treats Amplify Dynamics as an early-stage deeptech bet whose scientific premise is verifiable but whose commercial trajectory is not yet visible in public sources.

Data Accuracy: GREEN -- Confirmed by Crunchbase, the company website, and The Ganesha Lab.

Taxonomy Snapshot

Axis Value
Stage Pre-Seed
Business Model B2B
Industry / Vertical Cleantech / Climatetech (LNP purification for biotech)
Technology Type Hardware (acoustofluidics / microfluidics)
Geography North America
Funding Non-equity assistance (The Ganesha Lab)

Company Overview

PUBLIC

Amplify Dynamics describes itself as developer of an innovative ultrafiltration solution rooted in acoustofluidic and microfluidic separation [Amplify Dynamics website]. The founding narrative is academic in origin: the core purification method was invented by Gustavo during his doctoral work at the University of Chicago, after which he co-founded the company to bring the technique into industrial use, with an initial focus on lipid nanoparticle purification for therapeutics [Amplify Dynamics website] [The Ganesha Lab].

The company's headquarters and date of incorporation are not stated in the captured public sources, and Crunchbase lists the company without a confirmed founding year. What is on the public record is the relationship with The Ganesha Lab, a biotech accelerator that publicly announced its investment in Amplify Dynamics to advance LNP purification technology, and that lists the company among the cohort it backed in 2024 [The Ganesha Lab]. Crunchbase records two non-equity assistance entries against the company, dated January 1, 2024 and February 17, 2025, with amounts undisclosed [Crunchbase].

The milestones that are verifiable today are therefore narrow: technology invention at the University of Chicago, company formation around that invention, and acceptance into and continued support from The Ganesha Lab across two consecutive years. Customer names, pilot deployments, and revenue events are not publicly available.

Data Accuracy: YELLOW -- Founding narrative confirmed by company site and The Ganesha Lab; incorporation details and HQ not in public sources.

Product and Technology

MIXED

The product is an ultrafiltration system that uses acoustic waves and microfluidic channel design to separate target particles (initially lipid nanoparticles) from process fluid [Amplify Dynamics website]. The company positions this as a modern alternative to incumbent purification methods for LNPs, with the stated goal of "delivering ultra-pure lipid nanoparticles to accelerate the development of life-saving therapies" [The Ganesha Lab]. Crunchbase's profile likewise frames the offering as modern purification methods for lipid nanoparticles [Crunchbase].

Acoustofluidics, broadly, uses ultrasonic standing waves inside microfluidic channels to push particles of different size or compressibility into different streamlines, allowing label-free separation without the shear stress and membrane fouling associated with conventional tangential-flow filtration. The Amplify Dynamics public materials assert that the underlying separation technique was developed and validated in an academic setting at the University of Chicago [Amplify Dynamics website]. Independent peer-reviewed publication references, throughput numbers, recovery rates, and cost-per-dose figures are not disclosed in the captured sources, so any claim of performance superiority over tangential-flow filtration should be treated as a company-stated thesis until pilot data is published.

There are no public job postings or engineering blog entries from which to infer a tech stack or hardware supplier ecosystem. The public surface area of the product is therefore: a stated separation principle, a stated initial application (LNPs for therapeutics), and a stated outcome (higher purity to support downstream therapy development). Investors should expect the next public data points to come either from a CDMO partnership announcement or from a conference poster or preprint quantifying recovery and endotoxin reduction.

Data Accuracy: YELLOW -- Mechanism and application confirmed by company site and The Ganesha Lab; performance claims not independently verified.

Market Research and Opportunity

PUBLIC

Lipid nanoparticle manufacturing has moved from a niche delivery problem to a critical path bottleneck for an entire generation of therapeutics, and that is the market Amplify Dynamics is aimed at first.

LNPs are the dominant delivery vehicle for mRNA vaccines and a growing share of gene-editing and rare-disease pipelines. Demand was structurally reset by the COVID-19 mRNA vaccine programs and has since broadened into seasonal vaccines, oncology mRNA candidates, and CRISPR-based therapeutics that use LNPs to deliver guide RNA and editing machinery in vivo. Purification is one of the most expensive and lowest-yield steps in the LNP process: incumbent tangential-flow filtration can lose meaningful fractions of payload and concentrate process-related impurities, which forces additional polishing steps and drives up cost per dose. The company's stated value proposition, ultra-pure LNPs to accelerate therapy development, maps directly onto that pain point [The Ganesha Lab].

The captured research did not surface a named third-party TAM figure for LNP purification specifically, so this report does not assert one. The adjacent and substitute markets are observable, however. The buyers Amplify Dynamics would address are LNP-using therapeutics developers (large pharma mRNA programs and gene-therapy biotechs) and the CDMOs that manufacture for them. Substitutes include incumbent tangential-flow filtration systems sold by established bioprocess equipment vendors, chromatographic polishing steps, and emerging continuous-processing approaches. Regulatory tailwinds are real but indirect: the FDA's growing comfort with mRNA and LNP modalities increases the number of programs needing scaled purification, while CMC (chemistry, manufacturing and controls) expectations for LNP characterization keep rising, which favors any technology that can demonstrably improve purity and reproducibility.

The macro environment for biotech tools is mixed. Therapeutics funding has been compressed since 2022, which slows pilot budgets at small biotechs, but CDMO capex has held up because the underlying demand for clinical and commercial mRNA and gene-therapy supply continues. For a hardware vendor at Amplify Dynamics' stage, the practical implication is that the most reachable first customers are likely CDMOs and well-funded platform biotechs rather than early clinical sponsors.

Sizing reference Value Source
Confirmed company sizing claim None disclosed Company materials

Analyst takeaway: the market thesis here does not depend on a single TAM figure; it depends on whether LNP purification stays expensive and lossy enough that a hardware-led alternative can earn a place in validated GMP workflows. The cited evidence supports the pain point but does not yet quantify the prize.

Data Accuracy: YELLOW -- Demand drivers corroborated by The Ganesha Lab framing and the company's own positioning; no third-party TAM cited in captured sources.

Competitive Landscape

MIXED

Amplify Dynamics is positioned as a challenger to incumbent membrane-based purification in a market currently dominated by a handful of large bioprocess equipment vendors and a longer tail of academic and early-stage separation startups.

The captured sources do not name specific competitors, so this section is written as prose rather than a comparison table to avoid implying head-to-head matchups that are not in the public record. Readers should treat the competitive map below as an analyst characterization of the segment, not as a vendor-by-vendor benchmark.

At the incumbent layer, LNP purification today is largely performed using tangential-flow filtration cassettes and skids supplied by the major bioprocess equipment houses, alongside chromatography steps for further polishing. These vendors have deep installed bases inside CDMOs, validated GMP documentation packages, and field-service organizations that a pre-seed hardware company cannot match in the near term.

At the challenger layer, several academic spinouts in the United States and Europe have published on acoustofluidic and microfluidic separation for biological particles over the last decade. Most remain at the research-tool or single-use-device scale rather than at GMP-grade throughput. Amplify Dynamics' specific edge, as publicly stated, is that the core technique was invented by the founder during doctoral work and is being commercialized by the inventor rather than licensed out [Amplify Dynamics website]. That is a real but perishable advantage: it matters most in the first 24 to 36 months when the engineering trade-offs of the technique are still being learned, and matters less once a method becomes standard practice.

Where Amplify Dynamics is most exposed is the channel and validation question. A CDMO will not adopt a new purification step without process-development data, scale-up evidence, and a regulatory paper trail; building those assets takes capital and time the company has not yet publicly raised. The most plausible 18-month scenario is bifurcated. Winner if: Amplify Dynamics secures a paid pilot with a single named CDMO or platform mRNA developer and publishes recovery and purity data that materially beats tangential-flow filtration, at which point a priced seed round becomes straightforward. Loser if: the company spends the next 18 months on bench-scale demonstrations without a design partner, in which case the inventor's-edge advantage erodes as larger players publish their own acoustofluidic work or as continuous-processing alternatives mature inside incumbent product lines.

Data Accuracy: ORANGE -- Competitive framing is analyst characterization; no named competitors in captured sources.

Opportunity

PUBLIC

If Amplify Dynamics' purification step becomes a standard unit operation in LNP manufacturing, the company is positioned to sit inside the bill of materials of every LNP-based therapy that reaches commercial scale.

The headline opportunity. The single largest outcome is becoming the default purification technology for LNPs across CDMOs and platform mRNA developers. That outcome is reachable rather than aspirational because the underlying separation principle was invented and validated in an academic lab before the company existed, which compresses the technology-risk portion of the journey [Amplify Dynamics website], and because The Ganesha Lab, a biotech-specialized investor, has put non-equity backing behind the company in two consecutive years rather than one [Crunchbase] [The Ganesha Lab]. The company does not need to invent a market; LNP-based therapeutics already exist at commercial scale and the purification step is already in every process flow. The bet is on displacement, not creation.

Growth scenarios.

Scenario What happens Catalyst Why it's plausible
CDMO embed Amplify Dynamics' module is qualified inside one or more contract manufacturers' LNP service lines First paid pilot converts to a multi-site qualification agreement CDMOs face structural pressure to improve LNP yield and purity at lower cost, and the company's stated value proposition targets exactly that pain [The Ganesha Lab]
Platform biotech standard A platform mRNA or gene-therapy biotech adopts the technique as part of its in-house process and references it in regulatory filings Co-development with a single anchor biotech, followed by CMC inclusion in an IND LNP delivery is the rate-limiting step for several gene-editing modalities, raising the value of any purity gain [The Ganesha Lab]
Tools acquisition A bioprocess equipment incumbent acquires the company to add acoustofluidic purification to its catalog Published head-to-head data versus tangential-flow filtration at relevant scale Incumbent vendors have a long history of acquiring separation startups once GMP-grade data exists; the inventor-led origin makes the IP position cleaner than a licensed asset [Amplify Dynamics website]

What compounding looks like. The flywheel in regulated bioprocess is validation, not virality. Each CDMO or biotech that validates the device generates a process-development package, an extractables-and-leachables dossier, and an operator base that lowers the activation energy for the next adopter. Once one regulatory submission references the technology in its CMC section, every subsequent submission by other sponsors can reference that precedent, which is how new unit operations historically enter biomanufacturing. There is no public evidence that this flywheel has started yet, but the structure of the market is what makes the flywheel possible once a first reference customer exists.

The size of the win. The captured sources do not include a named third-party TAM for LNP purification, so this report does not put a dollar figure on the prize. The directional comparable, named without a forecast, is the bioprocess separation segment of the major life-sciences tools companies, where incumbent franchises in filtration and chromatography are valued in the multiple billions of dollars at the segment level (scenario, not a forecast). The realistic outcome distribution for Amplify Dynamics is wide: a successful CDMO embed could justify a tools-segment acquisition at a meaningful multiple of revenue; a failure to clear validation would leave the company as an interesting research-tool business. The asymmetry, given pre-seed entry pricing and a non-equity capitalization to date, is what makes the bet legible to a deeptech investor.

Data Accuracy: YELLOW -- Headline opportunity and scenarios grounded in cited positioning; comparable valuations are analyst characterization rather than confirmed transactions.

Sources

PUBLIC

  1. [Amplify Dynamics] Amplify Dynamics - Innovative Ultrafiltration Solution | https://amplify-dynamics.com/

  2. [Crunchbase] Amplify Dynamics - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/amplify-dynamics

  3. [Crunchbase] Non Equity Assistance - Amplify Dynamics - Crunchbase Funding Round Profile | https://www.crunchbase.com/funding_round/amplify-dynamics-non-equity-assistance--ca4751ef

  4. [Crunchbase] Amplify Dynamics - News & Analysis | https://www.www.crunchbase.com/organization/amplify-dynamics/news_and_analysis

  5. [The Ganesha Lab] The Ganesha Lab Invests in Amplify Dynamics to Drive Innovation in Lipid Nanoparticles Purification Technology | https://theganeshalab.com/the-ganesha-lab-invests-in-amplify-dynamics-to-drive-innovation-in-lipid-nanoparticles-purification-technology/

  6. [The Ganesha Lab] The Ganesha Lab: Driving biotech innovation in 2024 | https://theganeshalab.com/the-ganesha-lab-driving-biotech-innovation-in-2024/

  7. [LinkedIn] Sebastian Saldarriaga M - Amplify Dynamics | https://mx.linkedin.com/in/sebastian-saldarriaga-m-18062836

  8. [CB Insights] Amplify Dynamics Stock Price, Funding, Valuation, Revenue & Financial Statements | https://www.cbinsights.com/company/amplify-dynamics/financials

Articles about Amplify Dynamics

View on Startuply.vc